0.39
+0.0033(+0.85%)
Currency In USD
| Previous Close | 0.39 |
| Open | 0.38 |
| Day High | 0.4 |
| Day Low | 0.38 |
| 52-Week High | 0.83 |
| 52-Week Low | 0.22 |
| Volume | 133,527 |
| Average Volume | 189,175 |
| Market Cap | 15.39M |
| PE | -0.25 |
| EPS | -1.54 |
| Moving Average 50 Days | 0.39 |
| Moving Average 200 Days | 0.41 |
| Change | 0 |
If you invested $1000 in Athira Pharma, Inc. (ATHA) since IPO date, it would be worth $22.81 as of September 08, 2025 at a share price of $0.39. Whereas If you bought $1000 worth of Athira Pharma, Inc. (ATHA) shares 3 years ago, it would be worth $114.12 as of September 08, 2025 at a share price of $0.39.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
GlobeNewswire Inc.
Aug 14, 2025 11:00 AM GMT
BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
GlobeNewswire Inc.
May 13, 2025 3:00 PM GMT
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a cl
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
GlobeNewswire Inc.
Dec 06, 2024 10:30 PM GMT
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinica